Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin
Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy....
Gespeichert in:
| Veröffentlicht in: | Scientific reports Jg. 12; H. 1; S. 15593 - 9 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
16.09.2022
Nature Publishing Group Nature Portfolio |
| Schlagworte: | |
| ISSN: | 2045-2322, 2045-2322 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2–3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms. |
|---|---|
| AbstractList | Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2-3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms.Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2-3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms. Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2–3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms. Abstract Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2–3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms. Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves preemptive reduction of cumulative dose or reduction of dose intensity upon emergence of symptoms, despite the risk of reduced tumor efficacy. A predictive biomarker for dose-limiting CIPN could improve treatment outcomes by allowing providers to make informed decisions that balance both safety and efficacy. To identify a predictive biomarker of CIPN, markers of neurodegeneration neurofilament-light (NfL), glial fibrillary acidic protein (GFAP), tau and ubiquitin c-terminal hydrolase L1 (UCHL1) were assessed in serum of up to 88 subjects drawn 21 days following the first of 6 treatments with chemotherapeutics paclitaxel and carboplatin. Serum NfL and GFAP were increased with chemotherapy. Further, NfL change predicted subsequent onset of grade 2–3 CIPN during the remainder of the trial (mean treatment duration = 200 days) and trended toward stronger prediction of CIPN that remained unresolved at the end of the study. These results confirm previous reports that serum NfL is increased in CIPN and provide the first evidence that NfL can be used to identify subjects susceptible to dose-limiting paclitaxel and carboplatin induced CIPN prior to onset of symptoms. |
| ArticleNumber | 15593 |
| Author | Cho, E. Honigberg, L. Burgess, B. L. |
| Author_xml | – sequence: 1 givenname: B. L. surname: Burgess fullname: Burgess, B. L. organization: Development Sciences, Genentech Research and Early Development, Alector – sequence: 2 givenname: E. surname: Cho fullname: Cho, E. organization: Early Clinical Development, Genentech Research and Early Development – sequence: 3 givenname: L. surname: Honigberg fullname: Honigberg, L. email: honigberg.lee@gene.com organization: Development Sciences, Genentech Research and Early Development |
| BookMark | eNp9kkFvFCEUxyemJtbaL-CJxIuXscDADFxMTKO2SaMXPRMG3uyysjACs3E_iV9XdrdR20O5QB7__-89Hu9lcxZigKZ5TfA7gjtxlRnhUrSY0paIgfQtf9acU8x4SztKz_47v2guc97gujiVjMjz5vcXWFKcnNdbCAV5t1oXpDPSaE5gnSluB2h0cavTD0goTmgJCXL0O7DIrGEbyxqSnvetC3YxNThDcvMh5lE4sGdd1nvkAsrLuAFTMkpgwO1cWKFZG--K_gUe6VB5Oo1x9rq48Kp5Pmmf4fJ-v2i-f_r47fqmvfv6-fb6w11rOBlKy83UTTD0EyOMSjNIzkiPLbFCCiI1t8SYrp8w1pobPFqrBQPCWT8w2csJdxfN7Ylro96oObn60L2K2qljIKaV0qk440EJOwgz9qSb6MCwGSWebF9ZVrIRY0Eq6_2JNS_jFqypDa1deAB9eBPcWq3iTkkmSM9oBby9B6T4c4Fc1NZlA97rAHHJig41HeMYD1X65pF0E5cUaquOqiqpfagqelKZFHNOMP0thmB1mB11mh1VZ0cdZ0fxahKPTKb-UXHxULTzT1u7kzXXPGEF6V9VT7j-AHlG3s4 |
| CitedBy_id | crossref_primary_10_1007_s00415_025_13246_2 crossref_primary_10_1111_jns_12544 crossref_primary_10_2340_1651_226X_2024_39895 crossref_primary_10_1111_ene_16369 crossref_primary_10_1007_s00415_024_12679_5 crossref_primary_10_1177_01926233231179707 crossref_primary_10_1007_s00415_023_11624_2 crossref_primary_10_1016_j_biopha_2023_115535 crossref_primary_10_1016_j_tips_2024_08_001 crossref_primary_10_1186_s41983_024_00869_x crossref_primary_10_1177_02676591231213506 crossref_primary_10_3390_cancers15174216 crossref_primary_10_3390_cancers17060988 crossref_primary_10_3390_toxics11121004 crossref_primary_10_1007_s00018_024_05340_x crossref_primary_10_1080_17425255_2024_2401584 |
| Cites_doi | 10.1002/ana.24951 10.1097/01.NURSE.0000511823.41645.a1 10.1007/s00520-017-3780-y 10.1093/bja/aex229 10.1016/j.expneurol.2018.06.005 10.1007/s00204-020-02755-w 10.1212/WNL.0000000000003246 10.1016/j.critrevonc.2014.10.006 10.1007/s00520-019-04781-6 10.1371/journal.pone.0168707 10.1038/s41467-020-14612-6 10.1634/theoncologist.2016-0133erratum 10.1212/WNL.0000000000003587 10.1001/jamaneurol.2019.1534 10.1001/jamanetworkopen.2020.36695 10.3390/ijms20061451 10.1111/jns.12279 10.1001/jamaneurol.2016.0039 10.1038/s41598-019-56847-4 10.1634/theoncologist.2017-0690 10.1186/s12885-018-4869-5 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-022-18716-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_8d78cb613f2740cb90fd6154d94b0081 PMC9481642 10_1038_s41598_022_18716_5 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c517t-5cf3fe76f41429c7954160d1d89819a5d1cc36f00aa5c0bdda84e154674969f03 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000854795000027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Mon Nov 10 04:34:43 EST 2025 Tue Nov 04 02:07:03 EST 2025 Fri Sep 05 13:13:15 EDT 2025 Tue Oct 07 09:17:32 EDT 2025 Tue Nov 18 22:30:28 EST 2025 Sat Nov 29 02:07:10 EST 2025 Fri Feb 21 02:39:24 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c517t-5cf3fe76f41429c7954160d1d89819a5d1cc36f00aa5c0bdda84e154674969f03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/8d78cb613f2740cb90fd6154d94b0081 |
| PQID | 2715007160 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8d78cb613f2740cb90fd6154d94b0081 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9481642 proquest_miscellaneous_2715445007 proquest_journals_2715007160 crossref_primary_10_1038_s41598_022_18716_5 crossref_citationtrail_10_1038_s41598_022_18716_5 springer_journals_10_1038_s41598_022_18716_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-16 |
| PublicationDateYYYYMMDD | 2022-09-16 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Bridel (CR7) 2019; 76 Staff, Grisold, Grisold, Windebank (CR2) 2017; 81 Loprinzi (CR16) 2017; 10 Zajączkowska (CR20) 2019; 20 Ghoreishi (CR13) 2018; 18 Meregalli (CR9) 2020; 94 Mizrahi (CR14) 2021; 4 Gill, Merchant-Borna, Jeromin, Livingston, Bazarian (CR6) 2017; 88 Matsuoka (CR21) 2016; 11 Kim (CR8) 2020; 10 von Pawel (CR4) 2018; 23 Papa (CR5) 2016; 73 Kaplow, Iyere (CR11) 2017; 47 Mattsson (CR17) 2016; 87 Flatters, Dougherty, Colvin (CR1) 2017; 119 Le-Rademacher (CR18) 2017; 25 Havrilesky, Reiner, Morrow, Watson, Crawford (CR3) 2015; 93 Meregalli (CR10) 2018; 307 Khalil (CR12) 2020; 11 Mariotto (CR15) 2018; 23 García-Carbonero (CR22) 2017; 22 Tan, McCrary, Park, Trinh, Goldstein (CR19) 2019; 27 SJL Flatters (18716_CR1) 2017; 119 NP Staff (18716_CR2) 2017; 81 C Meregalli (18716_CR9) 2020; 94 J Le-Rademacher (18716_CR18) 2017; 25 CL Loprinzi (18716_CR16) 2017; 10 J von Pawel (18716_CR4) 2018; 23 D Mizrahi (18716_CR14) 2021; 4 Z Ghoreishi (18716_CR13) 2018; 18 C Meregalli (18716_CR10) 2018; 307 L Papa (18716_CR5) 2016; 73 AC Tan (18716_CR19) 2019; 27 J Gill (18716_CR6) 2017; 88 SH Kim (18716_CR8) 2020; 10 A Matsuoka (18716_CR21) 2016; 11 R Kaplow (18716_CR11) 2017; 47 N Mattsson (18716_CR17) 2016; 87 R Zajączkowska (18716_CR20) 2019; 20 S Mariotto (18716_CR15) 2018; 23 R García-Carbonero (18716_CR22) 2017; 22 M Khalil (18716_CR12) 2020; 11 C Bridel (18716_CR7) 2019; 76 LJ Havrilesky (18716_CR3) 2015; 93 |
| References_xml | – volume: 81 start-page: 772 year: 2017 end-page: 781 ident: CR2 article-title: Chemotherapy-induced peripheral neuropathy: A current review publication-title: Ann. Neurol. doi: 10.1002/ana.24951 – volume: 47 start-page: 67 year: 2017 end-page: 68 ident: CR11 article-title: Grading chemotherapy-induced peripheral neuropathy in adults publication-title: Nursing doi: 10.1097/01.NURSE.0000511823.41645.a1 – volume: 25 start-page: 3537 year: 2017 end-page: 3544 ident: CR18 article-title: Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials publication-title: Support. Care Cancer doi: 10.1007/s00520-017-3780-y – volume: 119 start-page: 737 year: 2017 end-page: 749 ident: CR1 article-title: Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): A narrative review publication-title: Br. J. Anaesth. doi: 10.1093/bja/aex229 – volume: 10 start-page: 25 year: 2017 ident: CR16 article-title: Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1 publication-title: J. Clin. Oncol. – volume: 307 start-page: 129 year: 2018 end-page: 132 ident: CR10 article-title: Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2018.06.005 – volume: 94 start-page: 2517 year: 2020 end-page: 2522 ident: CR9 article-title: Neurofilament light chain: A specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity publication-title: Arch. Toxicol. doi: 10.1007/s00204-020-02755-w – volume: 87 start-page: 1827 year: 2016 end-page: 1835 ident: CR17 article-title: Plasma tau in Alzheimer disease publication-title: Neurology doi: 10.1212/WNL.0000000000003246 – volume: 93 start-page: 203 year: 2015 end-page: 210 ident: CR3 article-title: A review of relative dose intensity and survival in patients with metastatic solid tumors publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2014.10.006 – volume: 23 start-page: 611 year: 2018 end-page: 654 ident: CR4 article-title: Randomized phase II trial of parsatuzumab (anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung cancer publication-title: Oncologist – volume: 10 start-page: 1 year: 2020 end-page: 9 ident: CR8 article-title: Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy publication-title: Sci. Rep. – volume: 27 start-page: 4771 year: 2019 end-page: 4777 ident: CR19 article-title: Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade publication-title: Support. Care Cancer doi: 10.1007/s00520-019-04781-6 – volume: 11 start-page: e0168707 year: 2016 end-page: e168714 ident: CR21 article-title: Bevacizumab exacerbates paclitaxel-induced neuropathy: A retrospective cohort study publication-title: PLoS ONE doi: 10.1371/journal.pone.0168707 – volume: 11 start-page: 1 year: 2020 end-page: 9 ident: CR12 article-title: Serum neurofilament light levels in normal aging and their association with morphologic brain changes publication-title: Nat. Commun. doi: 10.1038/s41467-020-14612-6 – volume: 22 start-page: 1281 year: 2017 end-page: 1281 ident: CR22 article-title: Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer publication-title: Oncologist doi: 10.1634/theoncologist.2016-0133erratum – volume: 88 start-page: 595 year: 2017 end-page: 602 ident: CR6 article-title: Acute plasma tau relates to prolonged return to play after concussion publication-title: Neurology doi: 10.1212/WNL.0000000000003587 – volume: 76 start-page: 1035 year: 2019 end-page: 1048 ident: CR7 article-title: Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2019.1534 – volume: 4 start-page: e2036695 year: 2021 ident: CR14 article-title: Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2020.36695 – volume: 20 start-page: 1451 issue: 6 year: 2019 ident: CR20 article-title: Mechanisms of chemotherapy-induced peripheral neuropathy publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20061451 – volume: 23 start-page: 174 year: 2018 end-page: 177 ident: CR15 article-title: Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies publication-title: J. Peripher. Nerv. Syst. doi: 10.1111/jns.12279 – volume: 18 start-page: 1 year: 2018 end-page: 6 ident: CR13 article-title: Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer 11 Medical and Health Sciences 1112 oncology and carcinogenesis publication-title: BMC Cancer – volume: 73 start-page: 510 year: 2016 end-page: 551 ident: CR5 article-title: Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2016.0039 – volume: 307 start-page: 129 year: 2018 ident: 18716_CR10 publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2018.06.005 – volume: 25 start-page: 3537 year: 2017 ident: 18716_CR18 publication-title: Support. Care Cancer doi: 10.1007/s00520-017-3780-y – volume: 10 start-page: 1 year: 2020 ident: 18716_CR8 publication-title: Sci. Rep. doi: 10.1038/s41598-019-56847-4 – volume: 20 start-page: 1451 issue: 6 year: 2019 ident: 18716_CR20 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20061451 – volume: 87 start-page: 1827 year: 2016 ident: 18716_CR17 publication-title: Neurology doi: 10.1212/WNL.0000000000003246 – volume: 22 start-page: 1281 year: 2017 ident: 18716_CR22 publication-title: Oncologist doi: 10.1634/theoncologist.2016-0133erratum – volume: 88 start-page: 595 year: 2017 ident: 18716_CR6 publication-title: Neurology doi: 10.1212/WNL.0000000000003587 – volume: 23 start-page: 611 year: 2018 ident: 18716_CR4 publication-title: Oncologist doi: 10.1634/theoncologist.2017-0690 – volume: 18 start-page: 1 year: 2018 ident: 18716_CR13 publication-title: BMC Cancer doi: 10.1186/s12885-018-4869-5 – volume: 94 start-page: 2517 year: 2020 ident: 18716_CR9 publication-title: Arch. Toxicol. doi: 10.1007/s00204-020-02755-w – volume: 23 start-page: 174 year: 2018 ident: 18716_CR15 publication-title: J. Peripher. Nerv. Syst. doi: 10.1111/jns.12279 – volume: 10 start-page: 25 year: 2017 ident: 18716_CR16 publication-title: J. Clin. Oncol. – volume: 47 start-page: 67 year: 2017 ident: 18716_CR11 publication-title: Nursing doi: 10.1097/01.NURSE.0000511823.41645.a1 – volume: 81 start-page: 772 year: 2017 ident: 18716_CR2 publication-title: Ann. Neurol. doi: 10.1002/ana.24951 – volume: 119 start-page: 737 year: 2017 ident: 18716_CR1 publication-title: Br. J. Anaesth. doi: 10.1093/bja/aex229 – volume: 76 start-page: 1035 year: 2019 ident: 18716_CR7 publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2019.1534 – volume: 73 start-page: 510 year: 2016 ident: 18716_CR5 publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2016.0039 – volume: 11 start-page: 1 year: 2020 ident: 18716_CR12 publication-title: Nat. Commun. doi: 10.1038/s41467-020-14612-6 – volume: 4 start-page: e2036695 year: 2021 ident: 18716_CR14 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2020.36695 – volume: 27 start-page: 4771 year: 2019 ident: 18716_CR19 publication-title: Support. Care Cancer doi: 10.1007/s00520-019-04781-6 – volume: 93 start-page: 203 year: 2015 ident: 18716_CR3 publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2014.10.006 – volume: 11 start-page: e0168707 year: 2016 ident: 18716_CR21 publication-title: PLoS ONE doi: 10.1371/journal.pone.0168707 |
| SSID | ssj0000529419 |
| Score | 2.465233 |
| Snippet | Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN involves... Abstract Management of chemotherapy-induced peripheral neuropathy (CIPN) remains a significant challenge in the treatment of cancer. Risk mitigation for CIPN... |
| SourceID | doaj pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 15593 |
| SubjectTerms | 631/378 692/4028 692/53 Biomarkers Carboplatin Chemotherapy Glial fibrillary acidic protein Humanities and Social Sciences Hydrolase multidisciplinary Neurodegeneration Neuronal-glial interactions Paclitaxel Peripheral neuropathy Protein gene product 9.5 Science Science (multidisciplinary) Tau protein Tumors Ubiquitin Ubiquitin carboxy-terminal hydrolase |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgC1IvvBGBgozEDaI6iRPHJ0RRK06rCoHUW-RXIFJIlmS36v4S_i4zjnerVKIXromTOPI8vpmxvyHknSuzwskENA0sYcwFqKJ0iY4lzzOXplqovPbNJsRyWV5cyPOQcBvDtsqdTfSG2vYGc-THqQDoAv6wYB9Xv2PsGoXV1dBC4y45QKYyviAHJ6fL86_7LAvWsXgiw2kZlpXHI3gsPFUGMViCwUKczzySJ-6foc2beyVvFEy9Hzp7-L9_8Ig8CAiUfppE5jG547on5P7Uk3L7lPyZ6DoakBSYC20xeKdqpIquBizqoHmkeGgf9_UMtK_pBhmD-vbSWQoS8Csc6drGEO2D3FiKXMqevKClnj0TmyBvadPRcaMxCzRSsLquwcwGhQgeWcOvXEtVB-9Tg-5XuF2ve0a-n51--_wlDt0bYpMnYh3nps5qJ4qaJ-DzjJA5YD9mE1tKQCEqt4kxWVEzplRumLZWldwBoCsEl4WsWfacLLq-cy8ItSo1RjKPLXlWc-kE04kVUmdppnkZkWS3gpUJ1ObYYaOtfIk9K6tp1StY9cqvepVH5P3-mdVE7HHr6BMUjP1IJOX2F_rhRxV0vCqtKI0GfFRDqM-Mlqy2ABi5lVwj9IrI0U4wqmApxupaKiLydn8bdBwLN6pz_WYawzkOi4iYieNsQvM7XfPTs4UjHQ8EmRH5sBPc64__-4df3j7XV-QwRRXCXhrFEVmsh417Te6Zy3UzDm-CFv4FKoM9NA priority: 102 providerName: ProQuest |
| Title | Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin |
| URI | https://link.springer.com/article/10.1038/s41598-022-18716-5 https://www.proquest.com/docview/2715007160 https://www.proquest.com/docview/2715445007 https://pubmed.ncbi.nlm.nih.gov/PMC9481642 https://doaj.org/article/8d78cb613f2740cb90fd6154d94b0081 |
| Volume | 12 |
| WOSCitedRecordID | wos000854795000027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nj5QwFG90VxMvxs-IrpOaeFOyBQqlR9fsRg87IUaT8UT6RSRBmMDMxvlL_Hd9rzDjsol68dIDLaXwe6_vPdr-HiGvXZ5kTkagaTAThlyAKkoX6VDyNHFxrIVKK59sQiyX-Woli2upvnBP2EgPPH6409yK3GgwOhXET8xoySoLVphbyTXaM5x9weu5FkyNrN6x5JGcTsmwJD8dwFLhaTKIvSIMEsJ0Zok8Yf_My7y5R_LGQqm3PxcPyP3JcaTvxgE_JLdc-4jcHVNJ7h6TnyPLRg0AQ1e0wZibqoEquu5xLQZnNYpn7XE7Tk-7im6R6KdrrpylANz36STWLoQgHeC2FCmQPedAQz3pJeYu3tG6pcNW48-bgcJk6Wr8IUEh8Eay7x-uoaqF_lSvuzXusmufkC8X55_ffwinpAuhSSOxCVNTJZUTWcUjMFVGyBRcNmYjm0twHlRqI2OSrGJMqdQwba3KuQM8MsFlJiuWPCVHbde6Z4RaFRsjmXcJeVJx6QTTkRVSJ3GieR6QaA9AaSZGckyM0ZR-ZTzJyxG0EkArPWhlGpA3h3vWIx_HX1ufIa6Hlsil7S-AhJWThJX_krCAnOylopwUfChjAZ40uGcZC8irQzWoJq63qNZ127EN59gsIGImTbMBzWva-psn-UYWHYgNA_J2L3e_H_7nF37-P174BbkXo55goozshBxt-q17Se6Yq0099AtyW6yEL_MFOT47XxafFl75oLyMCywFlMfFx8vi6y_cJTRJ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKAcGFZxGBAkaCE0TNw4njA0K8qlYtKw5F6s34FYi0JEuyW9hfwr_gNzLjJFttJXrrgWviPJx88_DM-BtCnrkizZ2IQdJAE4aMgygKF-tQsCx1SaK5ykrfbIJPJsXxsfi0Qf6Me2GwrHLUiV5R28ZgjHwn4eC6gD3Mo9ezHyF2jcLs6thCo4fFgVv-hCVb92r_Pfzf50my--Ho3V44dBUITRbzeZiZMi0dz0sWgy42XGTgk0Q2toUA66gyGxuT5mUUKZWZSFurCubA0cg5E7kooxTue4lchms5lpDxY76K6WDWjMVi2JsTpcVOB_YR97DBii_GpUmYrdk_3yZgzbc9W5l5Jj3rrd7uzf_te90iNwb_mr7pBeI22XD1HXK177i5vEt-92QkFcgBzJ1OMTRBVUcVnbWYskLlT5GSAKuWWtqUdIF8SM30xFkK-P4-bFhbhlVtQSosRaZoT80wpZ4bFFs8L2lV026hMcbVUbAprsK4DZ0pg5zov9yUqhrup1rdzLAYsd4iny_kq9wjm3VTu_uEWpUYIyLvObO0ZMLxSMeWC50mqWZFQOIRMdIMxO3YP2QqfQFBWsgeZRJQJj3KZBaQF6trZj1tybmj3yIQVyORctwfaNqvctBgsrC8MBq8vzLhLDJaRKUFd5hZwTQ6lgHZHoEoBz3YyVMUBuTp6jRoMExLqdo1i34MYzgsIHwN_msvtH6mrr55LnQkG4IldEBejoJy-vB_T_jB-e_6hFzbO_p4KA_3JwcPyfUExRe7huTbZHPeLtwjcsWczKuufezln5IvFy1AfwFe6pd7 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKeYgLb0SggJHgBNE6iRPHB4SAsqIqrPYAUm_BsR2IFJIl2S3sL-G_8OuYcZKtthK99cA1cV7OfDPjmfE3hDy1aZRYGQDSQBP6XAAUpQ1yX_I4smGYCxUXrtmEmM3SoyM53yF_xr0wWFY56kSnqE2jMUY-CQW4LmAPEzYphrKI-f701eKHjx2kMNM6ttPoReTQrn_C8q17ebAP__pZGE7ffXr73h86DPg6DsTSj3URFVYkBQ9AL2shY_BPmAlMKsFSqtgEWkdJwZhSsWa5MSrlFpyORHCZyIJFcN8L5KLgcYzo-hjON_EdzKDxQA77dFiUTjqwlbifDVZ_AS5T_HjLFrqWAVt-7ukqzVOpWmcBp9f_57m7Qa4Nfjd93QPlJtmx9S1yue_Eub5NfvckJSXgA-aBVhiyoKqjii5aTGWhUaBIVYDVTC1tCrpCnqSmOraGgtx_Hzayrf2yNoAWQ5FB2lE2VNRxhmLr5zUta9qtcox9dRRsjS0xnkMXSiNX-i9bUVXD_VSbNwssUqzvkM_nMit3yW7d1PYeoUaFWkvmPGoeFVxawfLACJlHYZTz1CPBKD2ZHgjdsa9IlbnCgijNeonLQOIyJ3FZ7JHnm2sWPZ3JmaPfoFBuRiIVuTvQtF-zQbNlqRGpzsErLELBmc4lKwy4ydxInqPD6ZG9USizQT922YlEeuTJ5jRoNkxXqdo2q34M5zjMI2ILClsvtH2mLr85jnQkIYKltUdejKA5efi_P_j-2e_6mFwB3GQfDmaHD8jVEJGMzUSSPbK7bFf2Ibmkj5dl1z5yqoCSL-eNn79qA6BI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neurofilament+light+as+a+predictive+biomarker+of+unresolved+chemotherapy-induced+peripheral+neuropathy+in+subjects+receiving+paclitaxel+and+carboplatin&rft.jtitle=Scientific+reports&rft.au=B.+L.+Burgess&rft.au=E.+Cho&rft.au=L.+Honigberg&rft.date=2022-09-16&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1038%2Fs41598-022-18716-5&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8d78cb613f2740cb90fd6154d94b0081 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |